Last reviewed · How we verify
Identification of Circulating Tumor Cells
At a glance
| Generic name | Identification of Circulating Tumor Cells |
|---|---|
| Sponsor | Fondation Hôpital Saint-Joseph |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Plasma Multi - Omics Detection for Evaluating Efficacy and Recurrence Risk in Oligometastatic Colorectal Cancer Conversion Therapy (NA)
- Circulating Tumor Cells in Lung Cancer Screening (NA)
- Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection
- Smartphone-enabled Hybrid Identification of Early CoLorectal Disease Using Blood-Based Cancer Testing Across TeXas (NA)
- Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC
- Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
- A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: